Grifols Diagnostic Solutions Inc.

Grifols Diagnostic Solutions Inc., a foreign-owned subsidiary of the global healthcare company Grifols, supplies blood bank analyzers, nucleic acid testing systems, immunohematology reagents, and associated laboratory diagnostic equipment to federal healthcare agencies as a prime contractor across 91 awards with no subcontract footprint. The company competes exclusively in full-and-open federal procurement with no set-aside designations across its portfolio.

Grifols is headquartered in Emeryville, California, and operates under NAICS codes centered on in-vitro diagnostic substance manufacturing (35 awards) and analytical laboratory instrument manufacturing (33 awards), with PSC codes dominated by in-vitro diagnostic substances, reagents, and test kits (38 awards) and laboratory equipment and supplies (27 awards). The company's federal work centers on clinical laboratory automation, blood bank testing systems, and specialized reagent supply for military treatment facilities and Veterans Affairs medical centers.

The Department of Veterans Affairs and Department of Defense dominate Grifols' customer base. VISN 15 leads by award count with 19 awards valued at $4.5 million combined potential value, followed by VISN 19 with ten awards at $674 thousand. However, the Air Education and Training Command (AETC) anchors the dollar concentration: ten awards to AETC carry $36.3 million combined potential value, representing more than half of Grifols' total federal pipeline. The Defense Health Agency and Defense Logistics Agency contribute $6.4 million and $5 million respectively. Together, the top five customer agencies account for 81% of combined potential value across all awards. Three of the highest-value awards exemplify Grifols' military healthcare posture: a $10 million single-award BPA with AETC for Procleix Panther Analyzer reagents at Wilford Hall Ambulatory Surgical Center (awarded April 2022, extended through April 2027); a $2.4 million firm fixed-price purchase order from the Defense Health Agency for annual dropship of FDA-approved Procleix reagents (Ultrio Elite, West Nile Virus, and Babesia assays) to Naval Hospital Okinawa through July 2029; and a $600 thousand firm fixed-price contract from the Defense Health Agency for preventive maintenance on a Procleix Panther nucleic acid test system at Naval Hospital Okinawa through August 2030.

Grifols holds multiple Indefinite Delivery Vehicles across federal agencies. The Critical Analyzers, Laboratory GSA Schedule 66-III vehicle anchors work at VISN 15, VISN 19, and VISN 20, with 12 task orders valued at $1.5 million combined potential value. A $1.25 million Indefinite Delivery Contract with VISN 15 for automated blood bank reagents supports cost-per-test blood analyzer supply. Two $10 million single-award blanket purchase agreements with AETC for Procleix Panther Analyzer reagents (one awarded April 2022 through April 2027, the second awarded October 2024 through April 2027) establish the vendor's most substantial standing vehicles. Recent IDV awards include a $935 thousand single-award Indefinite Delivery Contract with VISN 17 for automated immunohematology analyzer reagents and supplies through September 2030, and a $768 thousand single-award Indefinite Delivery Contract with VISN 23 for blood bank automation systems at Minneapolis VAMC through March 2030. The Defense Logistics Agency Troop Support Medical awarded a $5 million five-year Indefinite Delivery Contract under the SPE2DE program for laboratory supplies, reagents, diagnostics, and equipment.

Activity has been episodic. Grifols recorded six awards in 2022, eleven in 2023, five in 2024, eleven in 2025, and one in 2026 year-to-date. Only four awards (combined potential value $536 thousand) reach ultimate completion within the next twenty-four months, limiting near-term recompete exposure. Combined potential value across all 91 awards stands at $68.8 million, with $16.8 million obligated to date (24% of potential value). The vendor's recent award trajectory shows volatility in order volume but sustained dollar concentration in the AETC and Defense Health Agency relationships, which together represent approximately 63% of total potential value.